A medicine comprising a drug carrier comprising a retinoid derivative and/or vitamin A analogue as a component, and a drug for controlling the activity or growth of stellate cells, wherein the retinoid derivative and/or vitamin A analogue by bonding to or being included in the drug carrier enable(s) the specific transport of the drug to the stellate cells, and wherein the retinoid derivative and/or vitamin A analogue are/is selected from vitamin A, tretinoin, adapalene, or retinol palmitate, and Fenretinide (4-HPR), and wherein the drug for controlling the activity or growth of stellate cells is selected from (i) the group consisting of an siRNA, ribozyme, antisense nucleic acid, or DNA/RNA chimera polynucleotide, or a vector expressing same, that targets an extracellular matrix constituent molecule produced by stellate cells or one or more molecules having the function of producing or secreting the extracellular matrix constituent molecule, (ii) the group consisting of a ribozyme that specifically inhibits TIMP, an siRNA that specifically inhibits TIMP, an antisense TIMP nucleic acid, a truncated TGFβ type II receptor, a soluble TGFβ type II receptor, HGF, HGF expression vector, MMP gene-containing vector, an angiotensin-II type I receptor antagonist, a PDGF tyrosine kinase inhibitor, amiloride, compound 861, gliotoxin and adiponectin, and (iii) the group consisting of G-CSF, a thrombomodulin-like protein, and keratan sulfate oligosaccharide, and wherein the compound 861 is an apoptosis inducer.. wherein the retinoid derivative and/or vitamin A analogue by bonding to or being included in the drug carrier enable(s) the specific transport of the drug to the stellate cells, and wherein the retinoid derivative and/or vitamin A analogue are/is selected from vitamin A, tretinoin, adapalene, or retinol palmitate, and Fenretinide (4-HPR), and wherein the drug for controlling the activity or growth of stellate cells is selected from (i) the group consisting of an siRNA, ribozyme, antisense nucleic acid, or DNA/RNA chimera polynucleotide, or a vector expressing same, that targets an extracellular matrix constituent molecule produced by stellate cells or one or more molecules having the function of producing or secreting the extracellular matrix constituent molecule, (ii) the group consisting of a ribozyme that specifically inhibits TIMP, an siRNA that specifically inhibits TIMP, an antisense TIMP nucleic acid, a truncated TGFβ type II receptor, a soluble TGFβ type II receptor, HGF, HGF expression vector, MMP gene-containing vector, an angiotensin-II type I receptor antagonist, a PDGF tyrosine kinase inhibitor, amiloride, compound 861, gliotoxin and adiponectin, and (iii) the group consisting of G-CSF, a thrombomodulin-like protein, and keratan sulfate oligosaccharide, (i) the group consisting of an siRNA, ribozyme, antisense nucleic acid, or DNA/RNA chimera polynucleotide, or a vector expressing same, that targets an extracellular matrix constituent molecule produced by stellate cells or one or more molecules having the function of producing or secreting the extracellular matrix constituent molecule, (ii) the group consisting of a ribozyme that specifically inhibits TIMP, an siRNA that specifically inhibits TIMP, an antisense TIMP nucleic acid, a truncated TGFβ type II receptor, a soluble TGFβ type II receptor, HGF, HGF expression vector, MMP gene-containing vector, an angiotensin-II type I receptor antagonist, a PDGF tyrosine kinase inhibitor, amiloride, compound 861, gliotoxin and adiponectin, and (iii) the group consisting of G-CSF, a thrombomodulin-like protein, and keratan sulfate oligosaccharide, and wherein the compound 861 is an apoptosis inducer..